Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Atara Biotherapeutics, Inc.

< Previous 1 2 3 4 Next >
Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics Announces $31 Million Royalty Interest Financing Agreement with HealthCare Royalty
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics Announces Changes to Its Board of Directors
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics’ Ebvallo™ (tabelecleucel) Receives European Commission Approval as First Ever Therapy for Adults and Children with EBV+ PTLD
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics Presents Updated Clinical Data from Pivotal Phase 3 Trial (ALLELE) of Tab-cel® at the 64th American Society of Hematology (ASH) Annual Meeting
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics to Participate at the Evercore ISI 5th Annual HealthCONx Conference
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics to Participate at the Stifel Healthcare Conference
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics Announces Third Quarter 2022 Financial Results and Operational Progress
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics to Announce Third Quarter 2022 Financial Results on Tuesday, November 8, 2022
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics Presents New MRI and Updated Open-Label Extension Data from Phase 1 Study of ATA188 in Progressive Multiple Sclerosis at ECTRIMS 2022
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
CHMP Recommends Approval of Atara Biotherapeutics’ Ebvallo™ (tabelecleucel) for the Treatment of Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics to Receive Additional Near-Term Milestone Payment Under Updated Tabelecleucel (Tab-cel®) Commercialization Agreement with Pierre Fabre
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics to Participate in Cell Therapy Panel Discussion at the Citigroup 17th Annual Biopharma Conference
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics Announces Second Quarter 2022 Financial Results and Corporate Strategy Update
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics to Present at the Canaccord Genuity 42nd Annual Growth Conference
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics to Announce Second Quarter 2022 Financial Results on Monday, August 8, 2022
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics Announces Completion of the ATA188 Phase 2 EMBOLD Study Interim Analysis in Patients with Progressive MS
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics to Announce Completion of ATA188 Phase 2 EMBOLD Study Interim Analysis on Tuesday, July 12, 2022
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics Announces First Clinical Data from Ongoing Tab-cel® European Multicenter Expanded Access Program (EAP) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting and Update on Tab-cel EMA Regulatory Progress
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics Provides Update on Strategic Collaboration with Bayer
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics Announces First Quarter 2022 Financial Results and Operational Progress
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.